Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

Beach Season Peptide Guide: Protocol Comparison

Appetite Suppression Onset 3–5 days at starting dose 5–7 days at starting dose None (willpower-dependent) Tirzepatide's dual-receptor mechanism produces faster subjective appetite control, but both peptides outperform diet-only approaches for adherence Average

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • Appetite Suppression Onset
  • 3–5 days at starting dose
  • 5–7 days at starting dose
  • None (willpower-dependent)
  • Tirzepatide's dual-receptor mechanism produces faster subjective appetite control, but both peptides outperform diet-only approaches for adherence
  • Average Body Fat Reduction
  • 6–8% when combined with resistance training 4–5x/week and 500–700 cal deficit
  • 5–7% under identical training and dietary conditions
  • 2–3% (typically plateaus by week 4–5 due to metabolic adaptation)
  • GLP-1 therapy delays the ghrelin rebound and leptin suppression that sabotage traditional deficit protocols. The difference compounds over 8 weeks
  • Muscle Retention Rate
  • 95–98% lean mass preserved when protein ≥1.8g/kg daily
  • 94–97% lean mass preserved under same protein conditions
  • 85–90% (higher catabolism without appetite control allows protein underconsumption)
  • Peptides don't preserve muscle directly. They make eating sufficient protein during deficit psychologically easier, which is the actual mechanism
  • Cost (8-Week Total)
  • $240–400 compounded / $800–1,200 branded
  • $180–320 compounded / $600–1,000 branded
  • $0 for protocol itself
  • Compounded options make 8-week protocols financially accessible; branded versions carry identical active compound but 3–4× cost
  • Gastrointestinal Tolerability
  • 25–35% report nausea during titration (weeks 1–4)
  • 30–40% report nausea during titration
  • None
  • Slower titration (starting at 2.5mg tirzepatide or 0.25mg semaglutide) reduces discontinuation. Rushing to therapeutic dose is the primary adherence failure point